Cytokine-Stimulated 3H-Tdr Incorporation Into AML Blasts From Patient Samples Tested in LTC
Patient . | CPM Without Growth Factor4-150 . | Fold-Increase in 3H-Tdr Uptake Compared With Control Without Growth Factor . | ||||||
---|---|---|---|---|---|---|---|---|
. | . | IL-3 . | G-CSF . | SF . | FL . | IL-3 + SF . | IL-3 + FL . | IL-3 + SF + FL . |
1 | 88 ± 12 | 1 | 2 | 2 | 1 | 4 | 2 | 2 |
2 | 44 ± 4 | 126 | 2 | 24 | ND | 253 | ND | ND |
3 | 86 ± 5 | 30 | 2 | 5 | 2 | 56 | 65 | 85 |
4 | 97 ± 7 | 35 | 8 | 65 | 57 | 114 | 99 | 122 |
5 | 242 ± 36 | 5 | 4 | 1 | 39 | 7 | 54 | 52 |
6 | 85 ± 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
7 | 415 ± 78 | 16 | 3 | 3 | 3 | 20 | 22 | 24 |
8 | 270 ± 12 | 4 | 11 | 9 | 8 | 12 | 10 | 13 |
9 | 82 ± 19 | 3 | 1 | 2 | 2 | 3 | 5 | 7 |
10 | 339 ± 50 | 3 | 6 | 9 | 5 | 11 | 10 | 13 |
Patient . | CPM Without Growth Factor4-150 . | Fold-Increase in 3H-Tdr Uptake Compared With Control Without Growth Factor . | ||||||
---|---|---|---|---|---|---|---|---|
. | . | IL-3 . | G-CSF . | SF . | FL . | IL-3 + SF . | IL-3 + FL . | IL-3 + SF + FL . |
1 | 88 ± 12 | 1 | 2 | 2 | 1 | 4 | 2 | 2 |
2 | 44 ± 4 | 126 | 2 | 24 | ND | 253 | ND | ND |
3 | 86 ± 5 | 30 | 2 | 5 | 2 | 56 | 65 | 85 |
4 | 97 ± 7 | 35 | 8 | 65 | 57 | 114 | 99 | 122 |
5 | 242 ± 36 | 5 | 4 | 1 | 39 | 7 | 54 | 52 |
6 | 85 ± 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
7 | 415 ± 78 | 16 | 3 | 3 | 3 | 20 | 22 | 24 |
8 | 270 ± 12 | 4 | 11 | 9 | 8 | 12 | 10 | 13 |
9 | 82 ± 19 | 3 | 1 | 2 | 2 | 3 | 5 | 7 |
10 | 339 ± 50 | 3 | 6 | 9 | 5 | 11 | 10 | 13 |
Abbreviation: ND, not determined.
X̄ ± SEM.